<DOC>
	<DOCNO>NCT00400673</DOCNO>
	<brief_summary>The study set ass : 1 . A two-step , increasing-intensity remission induction phase . A conventional chemotherapy course ( ICE , plus G-CSF ) follow , unresponsive patient , sequential high-dose cytarabine ( plus G-CSF ) , aim provide early effective rescue many refractory case possible . 2 . A risk-oriented postremission consolidation phase . The objective adopt allogeneic stem cell transplantation ( alloSCT ) high-risk ( HR ) case , standard-risk ( SR ) one consolidate multicycle high-dose cytarabine-containing program , include use autologous stem cell plus G-CSF limit drug-related toxicity intercycle treatment delay .</brief_summary>
	<brief_title>A Risk-Oriented Therapeutic Strategy Adult Acute Myelogenous Leukemia</brief_title>
	<detailed_description>Adult AML difficult-to-treat illness biological therapeutic reason . As first point , many patient age &gt; 50 year and/or present significant comorbidity and/or AML-related risk feature ( poor risk cytogenetics , prior myelodysplasia , secondary AML ) . As second point , standard-type remission induction therapy ineffective 20 % patient , whereas application effective postremission consolidation option ( alloSCT , high-dose cytarabine course ) often flaw high-grade toxicity offset expect benefit , particularly old age group ( &gt; 50-55 year ) , therapy-related death rate see 5 % -10 % case ( chemotherapy ) ( transplant ) . Against background explorative study develop : 1 . All patient age 16-65 year consider eligible ( acute promyelocytic leukemia exclude ) , include antecedent diagnosis myelodysplasia/hematological disorder and/or secondary AML . Both age disease subtype selection criterion broad study adult AML , adhere closely report epidemiology disease . 2 . Remission induction attempt two-step regimen , consist conventional chemotherapy ( ICE : idarubicin/cytarabine/etoposide +G-CSF ) follow , case failure respond , sequential high dose-cytarabine cycle ( cytarabine 3 g/m2/bd day 1,2,8,9 ; idarubicin day 3 10 ; G-GSF ; cytarabine dose 2 g/m2 patient age &gt; 55 year ) . It hop choice would optimize salvage rate ( hence overall response rate ) , allow patient ( fit , uncomplicated one ) reach salvage phase , compare policy salvage usually give two failed induction course . 3 . Remission consolidation risk-oriented , risk define mixed clinico-cytogenetic model . Thus patient enter CR one/two cycle stratify HR SR accord report . Once define risk class , therapy consist alloSCT HR patient , 3 consecutive monthly cytarabine-based cycle ( 2 g/m2/bd day 1-5 ; idarubicin day 1,2 ) SR patient , cycle follow reinfusion limited amount autologous blood stem cell ( 1-2x10e6/kg CD34+ cell ) G-CSF . Blood stem cell collect follow early consolidation cycle intermediate-dose cytarabine plus G-CSF . HR patient unable/unfit proceed alloSCT offer instead SR-type multicycle cytarabine consolidation , whereas patient unable mobilize autologous stem cell treat one/two intermediate-dose cytarabine course ( ) . HR : high-risk cytogenetics intermediate-risk/normal cytogenetics FLT3 mutation and/or one additional clinical risk factor ( ) , i.e . total WBC &gt; 50x10e9/l , FAB subtype M0 , M6 M7 , prior myelodysplasia secondary AML , hepatosplenomegaly , late CR ( cycle 2 ) , favorable cytogenetics late CR ( cycle 2 ) . SR : favorable cytogenetics ( without associate high-risk abnormality CR cycle 1 ) intermediate-risk/normal cytogenetics without FLT3 mutation and/or without one additional clinical risk factor ( ) , i.e . total WBC &gt; 50x10e9/l , FAB subtype M0 , M6 M7 , prior myelodysplasia secondary AML , hepatosplenomegaly , late CR ( cycle 2 ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>age 1565 year , untreated AML ( de novo , secondary , myelodysplasiarelated , granulocytic sarcoma ) , untreated highrisk myelodysplasia ( RAEB , RAEBT ) , informed consent acute promyelocytic leukemia , comorbidity preclude intensive chemotherapy approach</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Acute myelogenous leukemia</keyword>
	<keyword>Adult patient</keyword>
	<keyword>Cytogenetic risk class</keyword>
	<keyword>Clinico-cytogenetic risk model</keyword>
	<keyword>Risk-oriented therapy</keyword>
</DOC>